Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic...

Area of Science:

• Cardiology
• Endocrinology
• Diabetology

Background:

• Diabetes mellitus significantly elevates cardiovascular (CV) event risk, especially with dyslipidemia and diabetic complications.
• Patients with hypercholesterolemia, diabetic retinopathy, and no prior coronary artery disease are a high-risk group for CV events.

Purpose of the Study:

• To investigate the incidence of CV events in patients with hypercholesterolemia and diabetic retinopathy under a treat-to-target strategy comparing intensive versus standard lipid-lowering therapy.
• To evaluate the safety and efficacy of intensive low-density lipoprotein cholesterol (LDL-C) reduction in preventing CV events in this specific high-risk diabetic population.

Main Methods:

• A multicenter, prospective, randomized, open-label, blinded end point study involving 5,042 patients.
• Patients were assigned to intensive statin therapy (LDL-C <70 mg/dL) or standard statin therapy (LDL-C 100-120 mg/dL).
• Follow-up averaged 37 months, with LDL-C levels and CV events meticulously recorded.

Main Results:

• The intensive group achieved a mean LDL-C of 76.5 mg/dL, while the standard group achieved 104.1 mg/dL at 36 months (P < 0.001).
• No significant difference in primary end point CV events was observed between the intensive and standard therapy groups (HR 0.84; P = 0.15).
• Exploratory analysis revealed a significant reduction in cerebral events in the intensive group (HR 0.52; P = 0.01), with no significant safety concerns.

Conclusions:

• Intensive statin therapy did not lead to a significant decrease in overall CV events or CV-associated deaths in this high-risk diabetic population.
• The observed effect may be attributed to a smaller-than-anticipated LDL-C difference between the groups.
• Further investigation into the benefits of achieving LDL-C <70 mg/dL with a treat-to-target approach in high-risk patients is warranted.